Roivant Sciences Director James C. Momtazee Receives Routine Equity Compensation

Executive Summary

On October 27, 2026, Roivant Sciences Ltd. ($ROIV) filed a Form 4 for Director James C. Momtazee detailing routine compensation-related transactions executed on October 23, 2026. The filing reports the award of 383 fully vested common shares under the Non-Employee Director Compensation Plan and the simultaneous net settlement of 77 shares at $36.49 per share to satisfy tax withholding obligations.

Transaction Breakdown

• Grant (Code A): 383 Common Shares awarded at $0.00 pursuant to the Issuer's Non-Employee Director Compensation Plan, fully vested on grant.
• Tax Withholding (Code F): 77 Common Shares surrendered to the issuer at a fair market value of $36.49 per share ($2,809.73 total value) to cover statutory tax obligations.
• Net Addition: +306 Common Shares.
• Post-Transaction Beneficial Ownership: 112,265 Common Shares held directly.

Market Significance

This filing represents standard non-employee director compensation rather than an open-market purchase or sale. Because the transaction is routine and pre-scheduled under Roivant's compensation program, it does not indicate a shift in insider sentiment and carries Low trading significance.